Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

User has diffuse thinning crown and uses combover with hair spray. Oral minoxidil showed amazing results for another user.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 24-year-old male started using finasteride and minoxidil for hair loss, noticing reduced hair fall but continued temple and frontal recession. He uses both oral and topical minoxidil, biotin, vitamin D, and coal tar shampoo, and experiences rare heart palpitations.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

A user is experiencing temple hair recession and is seeking alternatives to finasteride. They are considering castor oil, coconut oil, and derma rolling, and have seen some improvement with Zenegen.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A user shared their 1.5-year progress after a FUE crown transplant, using dutasteride and oral minoxidil, which improved their hairline and stabilized hair loss. They experienced dizziness from topical minoxidil but had no side effects from finasteride, dutasteride, or oral minoxidil.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

A 28 year old male experiencing diffuse thinning, chronic dandruff and scalp crust (seborrheic dermatitis), with replies discussing the use of topical fin for hormone imbalances and Nizoral for seb derm.

Eucapil (fluridil) may reduce hair shedding. It can be added to a regimen with finasteride and minoxidil.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The conversation humorously discusses an extensive and exaggerated hair loss treatment regimen, including finasteride, dutasteride, minoxidil, pyrilutamide, RU58841, and various other therapies. Despite the numerous treatments, the effectiveness is questioned, and the user humorously considers adding more minoxidil.

A regimen for hair loss, which includes using Nizoral shampoo twice daily, Minoxidil foam from the can, 5mg of Propecia crushed and snorted on weekends, and dermastamping directly to the head of the penis. Replies discuss potential sides and other treatments, as well as the idea that confidence is more attractive than hair.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.

Comparing scalp hair to facial hair, and the effects of DHT on growth. Possible treatments discussed include Minoxidil, finasteride and RU58841.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.